In addition, given what we now know about the heterogeneity of tauopathies with respect to structural conformation and neuroanatomical deposition, the predominant use of transgenic models harbouring FTD-MAPT mutations for investigating different tauopathies may limit the translational potential and is an important consideration when selecting the appropriate model. The gene discussed is MAPT; the disease is tauopathy.